These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33439067)

  • 1. Aspartylglucosaminuria: Clinical Presentation and Potential Therapies.
    Goodspeed K; Feng C; Laine M; Lund TC
    J Child Neurol; 2021 Apr; 36(5):403-414. PubMed ID: 33439067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
    Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
    Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical Gene Therapy with AAV9/AGA in Aspartylglucosaminuria Mice Provides Evidence for Clinical Translation.
    Chen X; Snanoudj-Verber S; Pollard L; Hu Y; Cathey SS; Tikkanen R; Gray SJ
    Mol Ther; 2021 Mar; 29(3):989-1000. PubMed ID: 33186692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.
    Arvio P; Arvio M; Kero M; Pirinen S; Lukinmaa PL
    J Med Genet; 1999 May; 36(5):398-404. PubMed ID: 10353787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria.
    Banning A; Gülec C; Rouvinen J; Gray SJ; Tikkanen R
    Sci Rep; 2016 Nov; 6():37583. PubMed ID: 27876883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A family with two children diagnosed with aspartylglucosaminuria-case report and literature review].
    Liu Y; Zou L; Meng Y; Zhang Y; Shi X; Ju J; Yang G; Hu L; Chen X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):455-9. PubMed ID: 25190167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring the CNS pathology in aspartylglucosaminuria mice.
    Tenhunen K; Uusitalo A; Autti T; Joensuu R; Kettunen M; Kauppinen RA; Ikonen S; LaMarca ME; Haltia M; Ginns EI; Jalanko A; Peltonen L
    J Neuropathol Exp Neurol; 1998 Dec; 57(12):1154-63. PubMed ID: 9862638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The T99K variant of glycosylasparaginase shows a new structural mechanism of the genetic disease aspartylglucosaminuria.
    Pande S; Guo HC
    Protein Sci; 2019 Jun; 28(6):1013-1023. PubMed ID: 30901125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amlexanox provides a potential therapy for nonsense mutations in the lysosomal storage disorder Aspartylglucosaminuria.
    Banning A; Schiff M; Tikkanen R
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):668-675. PubMed ID: 29247835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular pathogenesis of a disease: structural consequences of aspartylglucosaminuria mutations.
    Saarela J; Laine M; Oinonen C; von Schantz C; Jalanko A; Rouvinen J; Peltonen L
    Hum Mol Genet; 2001 Apr; 10(9):983-95. PubMed ID: 11309371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel mutation causing aspartylglucosaminuria reveals a mutation hotspot region in the aspartylglucosaminidase gene.
    Isoniemi A; Hietala M; Aula P; Jalanko A; Peltonen L
    Hum Mutat; 1995; 5(4):318-26. PubMed ID: 7627186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease.
    Ikonen E; Baumann M; Grön K; Syvänen AC; Enomaa N; Halila R; Aula P; Peltonen L
    EMBO J; 1991 Jan; 10(1):51-8. PubMed ID: 1703489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspartylglucosaminuria caused by a novel homozygous mutation in the AGA gene was identified by an exome-first approach in a patient from Japan.
    Yamamoto T; Shimojima K; Matsufuji M; Mashima R; Sakai E; Okuyama T
    Brain Dev; 2017 May; 39(5):422-425. PubMed ID: 28063748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase.
    Saarela J; von Schantz C; Peltonen L; Jalanko A
    Hum Mutat; 2004 Oct; 24(4):350-1. PubMed ID: 15365992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspartylglucosaminuria among Palestinian Arabs.
    Zlotogora J; Ben-Neriah Z; Abu-Libdeh BY; Sury V; Zeigler M
    J Inherit Metab Dis; 1997 Nov; 20(6):799-802. PubMed ID: 9427148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human aspartylglucosaminidase. A biochemical and immunocytochemical characterization of the enzyme in normal and aspartylglucosaminuria fibroblasts.
    Enomaa N; Heiskanen T; Halila R; Sormunen R; Seppälä R; Vihinen M; Peltonen L
    Biochem J; 1992 Sep; 286 ( Pt 2)(Pt 2):613-8. PubMed ID: 1530592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
    Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
    Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed profile of cognitive dysfunction in children with aspartylglucosaminuria.
    Harjunen EL; Laine M; Tikkanen R; Helenius P
    J Inherit Metab Dis; 2020 Mar; 43(2):318-325. PubMed ID: 31415096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.